中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

32 records (took 0.016 seconds)

    Recycling and accessory storage apparatus
    21.
    发明授权
    Recycling and accessory storage apparatus 失效
    回收和附件存储设备

    公开(公告)号：US08528474B2

    公开(公告)日：2013-09-10

    申请号：US12882548

    申请日：2010-09-15

    Applicant: Stuart Hamilton Monteith

    Inventor： Stuart Hamilton Monteith

    IPC: B30B9/30

    CPC classification number: B30B9/323

    Abstract: A recycling and accessory storage apparatus for crushing items and storing accessory devices, includes a housing having apertures therein. At least one of the apertures is adapted to store an accessory and at least one other aperture is adapted to allow an item to be inserted, crushed and ejected out of the apparatus.

    Abstract translation: 用于破碎物品和存储附件的回收利用和附件存储装置包括其中具有孔的壳体。 孔中的至少一个适于存储附件，并且至少一个其它孔适于允许物品被插入，压碎并从装置中弹出。

    SIMPLE HOME NETWORKING
    23.
    发明申请
    SIMPLE HOME NETWORKING 有权
    简单的家庭网络

    公开(公告)号：US20120136975A1

    公开(公告)日：2012-05-31

    申请号：US13367702

    申请日：2012-02-07

    Applicant: Stuart Hamilton ,  Pamela S. Lee ,  Archana Rao

    Inventor： Stuart Hamilton ,  Pamela S. Lee ,  Archana Rao

    IPC: G06F15/177

    CPC classification number: H04L41/085 ,  H04L41/0663 ,  H04L41/082 ,  H04L41/0886 ,  H04L41/5025

    Abstract: A network management system is provided for managing a computer network. The management system is configured to represent the computer network as having one of a plurality of defined network states. Once the state of the network has been identified, the management system can assist the user in making modifications to the computer network and in making recommendations to the user for possible modifications to the computer network. These modifications can include, for example, configuring network devices, removing network devices, replacing network devices, and adding new network devices.

    Abstract translation: 提供用于管理计算机网络的网络管理系统。 管理系统被配置为将计算机网络表示为具有多个定义的网络状态之一。 一旦已经识别出网络的状态，管理系统可以帮助用户对计算机网络进行修改，并向用户提出可能对计算机网络的修改的建议。 这些修改可以包括例如配置网络设备，去除网络设备，替换网络设备以及添加新的网络设备。

    2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents
    24.
    发明授权
    2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents 有权
    2'，4'-二氯联苯-4-基 - 羟基酮和相关化合物及其作为治疗剂的用途

    公开(公告)号：US07560597B2

    公开(公告)日：2009-07-14

    申请号：US12043568

    申请日：2008-03-06

    Applicant: Iain Robert Greig ,  Robert Jurgen van 't Hof ,  Stuart Hamilton Ralston

    Inventor： Iain Robert Greig ,  Robert Jurgen van 't Hof ,  Stuart Hamilton Ralston

    IPC: C07C49/245 ,  C07C33/26 ,  A61K31/15 ,  A61K31/47

    CPC classification number: C07C49/83 ,  C07C33/46 ,  C07C45/004 ,  C07C45/64 ,  C07C49/813 ,  C07C251/48 ,  C12N5/0643 ,  C12N2501/999

    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds (collectively referred to herein as “DCBP compounds”), and more particularly to compounds selected from compounds of the following formula and pharmaceutically acceptable salts, solvates, and hydrates thereof: wherein: n is independently 1, 2, 3, or 4; W is independently —C(═O)—, —CH(OH)—, or —C(═NOROX)—; ROX is independently —H or C1-3alkyl; J is independently: —H, —RE1, —C(═O)—RE2, —C(═O)—O—RE3, —C(═O)—O—S(═O)2ORE4, —C(═O)—(CH2)n—C(═O)ORE5, —C(═O)—(CH2)n—NRNE1RNE2, —C(═O)—(CH2)n—NRNE3—C(═O)RE6, —C(═O)—(CH2)n—C(═O)—NRNE4RNE5, or —P(═O)(ORE7)(ORE8); wherein each of RE1, RE2, RE3, RE4, RE5, RE6, and RE7 is independently: —H, C1-3alkyl, -Ph, or —CH2-Ph. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment and/or prevention, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of, inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activation in rheumatoid arthritis, osteoporosis, cancer associated bone disease, Paget's disease and the like.

    Abstract translation: 本发明一般涉及治疗化合物领域，更具体地涉及某些2'，4'-二氯联苯-4-基 - 羟基酮和相关化合物（本文统称为“DCBP化合物”），以及 更具体地涉及选自下式化合物及其药学上可接受的盐，溶剂合物和水合物的化合物：其中：n独立地为1,2,3或4; W独立地是-C（-O） - ， - CH（OH） - 或-C（-NOROX） - ; ROX独立地为-H或C 1-3烷基; （-O）-O-RE 3，-C（-O）-OS（-O）2OR 4，-C（-O） - （CH 2）n C（-O）OR e 5，-C（-O） - （CH 2）n -NRNE 1 R NE 2，-C（ - ） - （CH 2）n -NRNE 3 -C （O） - （CH 2）n C（-O）-NRNE 4 NRN 5或-P（-O）（ORE 7）（ORE 8）; 其中RE1，RE2，RE3，RE4，RE5，RE6和RE7各自独立地为：-H，C1-3烷基，-Ph或-CH2-Ph。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内在治疗和/或预防例如炎症和/或关节破坏和/或骨丢失中的用途 ; 由免疫系统的过度和/或不适当和/或延长的激活介导的疾病; 炎性和自身免疫性疾病，例如类风湿性关节炎，牛皮癣，牛皮癣性关节炎，炎性肠病，强直性脊柱炎等; 与骨丢失相关的疾病，例如与类风湿性关节炎中的过度破骨细胞活化相关的骨丢失，骨质疏松症，癌症相关的骨病，佩吉特氏病等。

    2',4'-DICHLORO-BIPHENYL-4-YL-HYDROXY-KETONES AND RELATED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
    25.
    发明申请
    2',4'-DICHLORO-BIPHENYL-4-YL-HYDROXY-KETONES AND RELATED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS 有权

    公开(公告)号：US20080221220A1

    公开(公告)日：2008-09-11

    申请号：US12043568

    申请日：2008-03-06

    Applicant: Iain Robert Greig ,  Robert Jurgen van 't Hof ,  Stuart Hamilton Ralston

    Inventor： Iain Robert Greig ,  Robert Jurgen van 't Hof ,  Stuart Hamilton Ralston

    IPC: A61K31/15 ,  C07C49/245 ,  A61K31/12 ,  A61K31/047 ,  A61P29/00 ,  C12N5/06 ,  C07C33/26 ,  C07C251/40

    CPC classification number: C07C49/83 ,  C07C33/46 ,  C07C45/004 ,  C07C45/64 ,  C07C49/813 ,  C07C251/48 ,  C12N5/0643 ,  C12N2501/999

    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds (collectively referred to herein as “DCBP compounds”), and more particularly to compounds selected from compounds of the following formula and pharmaceutically acceptable salts, solvates, and hydrates thereof: wherein: n is independently 1, 2, 3, or 4; W is independently —C(═O)—, —CH(OH)—, or —C(═NOROX)—; ROX is independently —H or C1-3alkyl; J is independently: —H, —RE1, —C(═O)—RE2, —C(═O)—O—RE3, —C(═O)—O—S(═O)2ORE4, —C(═O)—(CH2)n—C(═O)ORE5, —C(═O)—(CH2)n—NRNE1RNE2, —C(═O)—(CH2)n—NRNE3—C(═O)RE6, —C(═O)—(CH2)n—C(═O)—NRNE4RNE5, or —P(═O)(ORE7)(ORE8); wherein each of RE1, RE2, RE3, RE4, RE5, RE6, and RE7 is independently: —H, C1-3alkyl, -Ph, or —CH2-Ph. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment and/or prevention, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of, inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activation in rheumatoid arthritis, osteoporosis, cancer associated bone disease, Paget's disease and the like.

    Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions
    30.
    发明申请
    Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions 有权
    芳基烷基磺酰胺作为治疗骨质素的治疗剂

    公开(公告)号：US20080119555A1

    公开(公告)日：2008-05-22

    申请号：US11628084

    申请日：2005-05-23

    Applicant: Stuart Hamilton Ralston ,  Iain Robert Greig ,  Aymen Ibrahim Idris Mohamed ,  Robert Jurgen Van 'T Hof

    Inventor： Stuart Hamilton Ralston ,  Iain Robert Greig ,  Aymen Ibrahim Idris Mohamed ,  Robert Jurgen Van 'T Hof

    IPC: A61K31/18 ,  C12N5/00 ,  C07C311/17 ,  C07C311/29 ,  A61P37/00 ,  A61P19/08 ,  C07C311/40 ,  A61K31/192

    CPC classification number: C07C323/67 ,  C07C311/17 ,  C07C311/18 ,  C07C311/29 ,  C07C311/40 ,  C07C311/46 ,  C07F7/1804

    Abstract: The present invention pertains to certain aryl alkyl sulfonamides and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formula: wherein: Ar1 is independently C5-20aryl (e.g., biphenyl, phenanthryl, fluorenyl, or carbazolyl, most preferably biphenyl), and is optionally substituted; RN is independently —H, acyl, C5-20aryl-C1-7alkyl, C3-20heterocyclyl, or C1-7alkyl, and is optionally substituted; Ralk is a C2-10alkylene group, and is optionally substituted; and Q is independently —H or an organic group having from 1 to 30 atoms selected from carbon, nitrogen, oxygen, sulfur, phosphorus, fluorine, chlorine, bromine, and iodine (e.g., an oxy-type group, an amine-type group, etc.); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

    Abstract translation: 本发明涉及某些芳基烷基磺酰胺及其衍生物，其特别是抑制破骨细胞存活，形成和/或活性; 和/或抑制骨吸收，更具体地涉及下式的化合物：其中：Ar 1独立地是C 5-20-20芳基（例如，联苯基，菲基，芴基， 或咔唑基，最优选联苯基），并且任选被取代; R N独立地是-H，酰基，C 5-20芳基-C 1-7烷基，C 3-20环烷基， 或杂环基，或C 1-7烷基，并且任选被取代; 烷基是C 2-10亚烷基，并且是任选被取代的; 和Q独立地是-H或选自碳，氮，氧，硫，磷，氟，氯，溴和碘的1至30个原子的有机基团（例如氧基，胺类基团 等）; 和其药学上可接受的盐，溶剂合物，酰胺，酯，醚，化学保护形式及其前药。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以抑制破骨细胞存活，形成和/或活性，以及​​抑制破骨细胞介导的病症和/或 其特征在于骨吸收，治疗诸如骨质疏松症，类风湿性关节炎，癌症相关的骨病，佩吉特氏病等骨病症; 和/或治疗与炎症或免疫系统的激活相关的病症。

Patent Agency Ranking